Research Progress on Regulatory B Cells in Systemic Lupus Erythematosus

Wang, Tao; Mei, Yongjun; Li, Zhijun

doi:10.1155/2019/7948687

Cited by 25 publications

(21 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although various phenotypes of Bregs have been reported, such as CD24 hi CD38 hi , CD24 hi CD27 + , CD25 hi CD71 hi CD73 lo , and CD19 + Tim1 + B subsets, the suppressive functions of Bregs via secretion of IL-10 and IL-35 have highlighted a regulatory role of Bregs in maintaining immune homeostasis in human. Future studies on the impaired inhibitory effects of Bregs may lead to the clinical applications of Breg cell therapy in SLE [163]. Thus, a combination of in vitro expansion of Bregs and adoptive transfer of autologous Bregs may restore the immune regulatory functions of Bregs and effectively suppress effector T cell response in SLE [164].…”

Section: Perspectivesmentioning

confidence: 99%

Multiple Functions of B Cells in the Pathogenesis of Systemic Lupus Erythematosus

Wang

et al. 2019

IJMS

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by excessive autoantibody production and multi-organ involvement. Although the etiology of SLE still remains unclear, recent studies have characterized several pathogenic B cell subsets and regulatory B cell subsets involved in the pathogenesis of SLE. Among pathogenic B cell subsets, age-associated B cells (ABCs) are a newly identified subset of autoreactive B cells with T-bet-dependent transcriptional programs and unique functional features in SLE. Accumulation of T-bet+ CD11c+ ABCs has been observed in SLE patients and lupus mouse models. In addition, innate-like B cells with the autoreactive B cell receptor (BCR) expression and long-lived plasma cells with persistent autoantibody production contribute to the development of SLE. Moreover, several regulatory B cell subsets with immune suppressive functions have been identified, while the impaired inhibitory effects of regulatory B cells have been indicated in SLE. Thus, further elucidation on the functional features of B cell subsets will provide new insights in understanding lupus pathogenesis and lead to novel therapeutic interventions in the treatment of SLE.

show abstract

Section: Perspectivesmentioning

confidence: 99%

Multiple Functions of B Cells in the Pathogenesis of Systemic Lupus Erythematosus

Wang

et al. 2019

IJMS

View full text Add to dashboard Cite

show abstract

“…IL-10 as an anti-inflammatory cytokine has the characteristics of cytokines as cytokines T-regulator cells especially T regulator type 1 cells (Tr1) which under normal circumstances can inhibit the response of B cells which is an independent effect of IL-10. IL-10 itself is not only produced by T-reg cells but also produced by other T-helper cells that have regulatory functions, besides IL-10 is also a cytokine that plays a role in the maturation and differentiation factors of B cells, so as to increase survival, proliferation, isotype changes, and B cell differentiation to plasma cells [23], [24].…”

Section: Discussionmentioning

confidence: 99%

“…A study by Su et al demonstrated the involvement of microRNA (miRNAs) in the stimulation of IL-10 in SLE. The dysregulation of miR-199-3p expression increases IL-10 production which targets Poly (ADP-ribose) polymerase-1 which is a serological marker found in SLE patients and is associated with inflammatory factors and cytokines, but the role of miRNA in the pathogenesis of SLE is still being evaluated, especially its impact on the clinical and activity of SLE disease [23], [24], [25], [26].…”

Section: Discussionmentioning

confidence: 99%

The Comparison of Interleukin-17 and Interleukin-10 with Systemic Lupus Erythematosus Disease Activity

Elvira¹,

Rengganis²,

Hidayat³

et al. 2020

Open Access Maced J Med Sci

View full text Add to dashboard Cite

AIM: This study was conducted to compare means of interleukin-17 (IL-17) (Th17 cytokines) and interleukin-10 (IL-10) (T-regulatory cytokines) as pro-inflammatory and anti-inflammatory cytokine with disease activity of systemic lupus erythematosus (SLE) and to investigate correlation between IL-17 cytokine serums with IL-10 in SLE patients. METHODS: This study recruited total of 68 SLE patients which included 34 active and 34 inactive patients based on MEX-SLEDAI as disease activity tool measurement and subjects were selected using consecutive sampling method. Blood samples were taken from subjects and IL-17 and IL-10 were measured using ELISA method. Data were analyzed with SPSS 26 software. RESULTS: Mean IL-17 was 19.67 ± 1.299 pg/ml in active SLE group and 19.78 ± 1.187 pg/ml in inactive group. Median of IL-10 in active group was 3.63 pg/ml and in inactive group was 2.52 pg/ml, respectively. No significant mean differences were found of IL-17 and IL-10 between active and inactive SLE patients (p > 0.005). We found significant positive correlation between IL-17 and IL-10 (p < 0.005; r = 0.529). CONCLUSION: There were no significant mean differences of IL-17 and IL-10 between active and inactive SLE patients. However, we found elevated result of IL-10 in active SLE than inactive. There was positive correlation between IL-17 and IL-10.

show abstract

“…However, IL-35 secreted by CD4 + CD25 + FOXP3 + regulatory T lymphocytes (Tregs) has a significant immunosuppressive effect in colon cancer and pancreatic cancer and is negatively related to the prognosis of patients ( Zeng et al, 2013 ; Nicholl et al, 2014 ). On the other hand, IL-35 secreted by Breg cells can negatively regulate the immune response of human systemic lupus erythematosus, inhibit the release of a variety of pro-inflammatory cytokines, and slow down the progression of the disease ( Wang et al, 2019b ). In animal experiments, IL-35 produced by activated Breg cells can significantly improve T cell-mediated encephalomyelitis and inhibit the growth of Salmonella in mice ( Shen et al, 2014 ).…”

Section: Introductionmentioning

confidence: 99%

Potential therapeutic effects of interleukin-35 on the differentiation of naïve T cells into Helios+Foxp3+ Tregs in clinical and experimental acute respiratory distress syndrome

Wang

Xie

et al. 2021

Molecular Immunology

View full text Add to dashboard Cite

Regulatory T lymphocytes are important targets for the treatment of acute respiratory distress syndrome (ARDS). IL-35 is a newly identified IL-12 cytokine family member that plays an important protective role in a variety of immune system diseases by regulating Treg cell differentiation; however, the role of IL-35 in the pathogenesis of ARDS is still unclear. Here, we found that IL-35 was significantly elevated in adult patients with ARDS compared to controls. Additionally, IL-35 was positively and significantly correlated with IL-6, IL-10 and the oxygenation index (PaO2/FiO2 ratio) but negatively correlated with TNF-α, IL-1β and APACHE II score during ARDS. Moreover, the proportion of Treg/CD4 + cells in the peripheral blood of ARDS patients and the expression of NF-κB in PMBCs were significantly higher than in healthy individuals. Recombinant IL-35 improved survival in a murine model of CLP-induced ARDS. Additionally, IL-35 administration decreased the inflammatory response, as reflected by lower levels of cytokines (including IL-2, TNF-α, IL-1β and IL-6) and less lung damage in CLP-induced ARDS. Furthermore, recombinant IL-35 reduced the apoptosis of lung tissue and the expression of NF-κB signalling in a CLP-induced ARDS model and increased the proportion of Treg cells in spleen and peripheral blood. In vitro experiments revealed that IL-35 can affect the phosphorylation of STAT5 during differentiation of naïve CD4 + T lymphocytes into Foxp3 + Helios + Tregs. Our findings suggest that IL-35 attenuates ARDS by promoting the differentiation of naïve CD4 + T cells into Foxp3 + Helios + Tregs, thereby providing a novel tool for anti-ARDS therapy.

show abstract

Research Progress on Regulatory B Cells in Systemic Lupus Erythematosus

Cited by 25 publications

References 48 publications

Multiple Functions of B Cells in the Pathogenesis of Systemic Lupus Erythematosus

Multiple Functions of B Cells in the Pathogenesis of Systemic Lupus Erythematosus

The Comparison of Interleukin-17 and Interleukin-10 with Systemic Lupus Erythematosus Disease Activity

Potential therapeutic effects of interleukin-35 on the differentiation of naïve T cells into Helios+Foxp3+ Tregs in clinical and experimental acute respiratory distress syndrome

Contact Info

Product

Resources

About